Liquidia Corporation reported estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for the full year 2025.
The company received over 2,800 unique patient prescriptions since the launch of YUTREPIA in June 2025.
Positive cash flow of more than $30 million was generated during the fourth quarter of 2025.
Successful Commercial Launch
The successful commercial launch of YUTREPIA in 2025 across patient populations marked a transformational year for Liquidia.
Strong Financial Performance
Preliminary unaudited figures show net product sales of $148.3 million in 2025 with positive cash flow exceeding $30 million in Q4.
Pipeline Advancements
Plans to advance clinical programs in 2026 to differentiate YUTREPIA and L606, aiming to set new standards in serious diseases like IPF and PH-COPD.
- Liquidia's continued momentum in adoption of YUTREPIA reflects strong execution and growing physician confidence in the product.
- The company's financial highlights demonstrate a robust performance with significant positive cash flow and steady growth in net product sales.
Liquidia Corporation's preliminary results for YUTREPIA in 2025 showcase a successful year with strong sales and strategic advancements. The company's focus on further clinical development indicates a promising future in the respiratory and vascular disease markets.